Cannabics Pharmaceuticals Stock Performance
| CNBX Stock | USD 0.01 0.00 0.00% |
On a scale of 0 to 100, Cannabics Pharmaceuticals holds a performance score of 3. The firm shows a Beta (market volatility) of -1.38, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cannabics Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Cannabics Pharmaceuticals is expected to outperform it. Please check Cannabics Pharmaceuticals' variance and kurtosis , to make a quick decision on whether Cannabics Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Cannabics Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent fundamental drivers, Cannabics Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.4 M | |
| Total Cashflows From Investing Activities | 25.2 K |
Cannabics |
Cannabics Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1.00 in Cannabics Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Cannabics Pharmaceuticals or generate 0.0% return on investment over 90 days. Cannabics Pharmaceuticals is currently generating 0.4139% in daily expected returns and assumes 8.7466% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of pink sheets are less volatile than Cannabics, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cannabics Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannabics Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cannabics Pharmaceuticals, and traders can use it to determine the average amount a Cannabics Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0473
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CNBX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.75 actual daily | 77 77% of assets are less volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Cannabics Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cannabics Pharmaceuticals by adding it to a well-diversified portfolio.
Cannabics Pharmaceuticals Fundamentals Growth
Cannabics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cannabics Pharmaceuticals, and Cannabics Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cannabics Pink Sheet performance.
| Return On Equity | -42.89 | |||
| Return On Asset | -1.0 | |||
| Current Valuation | 6.67 M | |||
| Shares Outstanding | 1.26 M | |||
| Price To Earning | 31.09 X | |||
| Price To Book | 20.39 X | |||
| Price To Sales | 7,566 X | |||
| EBITDA | (3.52 M) | |||
| Cash And Equivalents | 96.28 K | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1.6 M | |||
| Debt To Equity | 0.48 % | |||
| Book Value Per Share | (1.57) X | |||
| Cash Flow From Operations | (1.68 M) | |||
| Earnings Per Share | (3.80) X | |||
| Total Asset | 811.17 K | |||
About Cannabics Pharmaceuticals Performance
Evaluating Cannabics Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cannabics Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cannabics Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Cannabics Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cannabics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cannabics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cannabics Pharmaceuticals had very high historical volatility over the last 90 days | |
| Cannabics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cannabics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Cannabics Pharmaceuticals currently holds 1.6 M in liabilities with Debt to Equity (D/E) ratio of 0.48, which is about average as compared to similar companies. Cannabics Pharmaceuticals has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cannabics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cannabics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cannabics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cannabics to invest in growth at high rates of return. When we think about Cannabics Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.72 M) with profit before overhead, payroll, taxes, and interest of 7.16 K. | |
| Cannabics Pharmaceuticals currently holds about 96.28 K in cash with (1.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of Cannabics Pharmaceuticals shares are held by company insiders |
- Analyzing Cannabics Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cannabics Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cannabics Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cannabics Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cannabics Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cannabics Pharmaceuticals' pink sheet. These opinions can provide insight into Cannabics Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.